Evolution of Drug resistance

Slides: https://www.andreashandel.com/presentations/

2023-10-17

Self-replicating (living) entities evolve

Interesting Evolutionary ID Topics

  • Immune escape (e.g. influenza, SARS-CoV-2, HIV)
  • Evolution of virulence (e.g. reduced mortality of myxomatosis virus in rabbits)
  • Evolution in response to vaccines (why do we need a new flu vaccine every year but a 30+ year old vaccine still works well against measles?)
  • Evolution of drug resistance (within-host drug resistance evolution of HIV, resistance to antibacterial drugs for a lot of bacteria – MRSA, XDR-TB,…)

Evolution of Drug Resistance

  • Resistance of pathogens to drugs is a major public health problem.
  • We need to understand how and why resistance arises and spreads, and what to do about it.

Evolutionary Dynamics 101

Evolution has several main “ingredients”

  • Mutation (including recombination, etc.)
  • Random changes (drift)
  • Selection

Mutations

  • When something (e.g. RNA, DNA, proteins) is copied/produced, changes (mistakes) happen.
  • Most of the time, the rate at which changes happen is constant.
    • High for RNA-based organism
    • Low for DNA-based organisms
  • Sometimes, rates of change/mutation can be influenced by the environment (e.g. increased mutation of “stressed” bacteria).

Selection

  • Different mutants are “selected” based on their fitness.
  • Fitness is being measured in different ways. Ultimately, what counts for pathogens is the ability to transmit from host to host and keep the chain going.
  • The mutant with the higher fitness (better able to transmit) “wins” and the one with the lower fitness tends to die out or remain at low levels.

Fitness of Mutants

  • Most organisms are already relatively fit.
  • Most mutations lead to mutants with reduced fitness compared to their ancestor (wild-type).
  • Those are often called deleterious mutations.

Fitness of Mutants

  • Occasionally, a mutation leads to a mutant with increased fitness.
  • There are more ways/mutations to increase fitness a bit, only a few increase fitness by a lot.

Mutation-selection balance

  • Mutants are constantly generated.
  • Most of the time, mutants are less fit (i.e. reproduce/transmit less well) and are out-competed by the wild-type strain.
  • Selection acts against mutants and purges them.
  • The number of mutants is determined by the rate of mutations (production) and the strength of (negative) selection.

Mutation-selection balance

Impact of Interventions on Fitness

  • Interventions generally do not change the mutation process.
  • Interventions can impact the selection process.
  • Certain interventions (e.g. drugs, vaccines) can lower the fitness of the wild-type. This gives the mutant a selective fitness and it can take over.

Fitness and Environment

Modeling drug resistance evolution

  • Drugs can (but don’t have to) lead to the evolution and emergence of resistance.
  • Models can help understand evolutionary dynamics.
  • Models can be used to explore different scenarios and try to predict best strategies to minimize resistance emergence, maximize overall benefit, etc.
  • Good references to get started & learn more:
    • Temime et al. (2008) Epid Inf
    • zur Wiesch et al. (2011) Lancet Inf Dis

Example: Influenza drug resistance

  • Assume a new pandemic flu strain emerges.
  • The strain is initially susceptible to antivirals.
  • Antivirals reduce the fitness of the wild-type strain, thus a resistant strain might emerge and spread.

Example: Influenza drug resistance

The question/problem:

  • No treatment = no reduction in wild-type (wt) infections but also no reduction in wt fitness, therefore no resistance emergence.
  • Lots of treatment = large reduction in wt infections but also strong reduction in wt fitness and potentially rapid emergence and spread of resistance.
  • What is the best population-level of antiviral treatment to minimize total cases?

Example: Flu drug resistance evolution

Answering the question:

  • Pick some population-level of treatment.
  • Simulate a number of pandemics. At end of each simulation, count total number of cases (both wt and resistant infected). Compute average over all simulations for a given treatment level.
  • Change value for treatment level, repeat.
  • Report distribution of cases as function of treatment level.

DSAIDE Exploration

R package to explore infectious disease models without having to write code:

https://ahgroup.github.io/DSAIDE/

Install or run online, then find the “Evolution of Drug Resistance” app.

Loosely based on Handel et al. 2009 JTB “Antiviral resistance and the control of pandemic influenza: The roles of stochasticity, evolution and model details”

Questions?

https://phdcomics.com/

  • Slides: https://www.andreashandel.com/presentations/